| 生物活性 |
CKD-712 is an orally effective multi-target tetrahydroisoquinoline derivative and a potent inhibitor of the NF-κB pathway that selectively inhibits MMP-9 without affecting MMP-2, downregulates the expression of proteins such as TNF-α, IL-6, cyclin A, cyclin B, and CDK-1, and activates the PI3K/Akt signaling pathway; by blocking NF-κB activation and nuclear translocation, downregulating inflammatory factors and pro-metastatic proteins, and inducing G2/M phase arrest in tumor cells, it inhibits cancer cell invasion, and can be used for research on sepsis, myocardial ischemia-reperfusion injury, and non-small cell lung cancer. |
体外研究 (In Vitro) |
CKD-712 (5-30 μg/mL; 48 h) 可剂量依赖性地抑制人肺腺癌细胞 A549 的增殖,其中 30 μg/mL 可使增殖抑制率达到 60%,且不会诱导细胞死亡。
CKD-712 (30-50 µg/ml; 48 h) 可诱导 A549 细胞发生 G2/M 期细胞周期停滞。
CKD-712 (30 µg/ml; 48 h) 可抑制人肺癌 A549 细胞中细胞周期蛋白 A、细胞周期蛋白 B 及 CDK-1 的表达。
CKD-712 (30 µg/ml; 48 h) 可剂量依赖性地抑制人肺癌 A549 细胞的有丝分裂。
CKD-712 (20 µg/ml; 12 h, 24 h) 可抑制腺癌细胞的生长。
CKD-712 (10 µg/ml; 1 h; 预孵育) 可抑制 TNF-α 诱导的人肺癌 A549 细胞中 NF-κB 的活化。
CKD-712 (5-30 µg/ml; 24 h) 可抑制人肺癌 A549 细胞中参与增殖、抗凋亡及血管生成的相关蛋白的表达。
CKD-712 (30 µg/ml; 48 h) 可剂量依赖性地抑制人肺癌 A549 细胞中 MMP-9 的活性,且不影响 MMP-2 的活性。
Cell Proliferation Assay
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Significantly suppressed cell proliferation in a dose-dependent manner up to 60% at 30 μg/mL. |
Western Blot Analysis
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Suppressed the expression of cyclin A, cyclin B and CDK-1 proteins. |
Western Blot Analysis
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Inhibited TNF-α-induced NF-κB p65 nuclear translocation; suppressed proteins involved in proliferation, anti-apoptosis, and angiogenesis including Mcl-1, COX-2, XIAP, and VEGF in A549 cells. |
Cell Invasion Assay
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Inhibited A549 cell invasion in a dose-dependent manner. |
Cell Migration Assay
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
20 μg/mL |
| Incubation Time: |
12 h, 24 h |
| Result: |
Inhibited A549 cell migration as evidenced by controlled wound closure compared to test. |
Cell Cycle Analysis
| Cell Line: |
A549 human lung carcinoma cells |
| Concentration: |
5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Induced marked cell cycle changes with an increase in the fraction of cells in G2/M, indicating significant G2/M cell death. |
|
体内研究 (In Vivo) |
CKD-712 (1-20 mg/kg; 腹腔注射;单次给药;LPS 前 30 分钟) 可剂量依赖性地预防小鼠中 LPS 诱导的低体温症,在 LPS 攻击后 5 和 7 小时维持显著更高的体温。
CKD-712 (1-3 mg/kg/ 天;腹腔注射;每日一次;共 4 次给药) 可提升 CLP 诱导的多微生物败血症小鼠的存活率,在以 1 mg/kg/ 天的剂量给药 4 天的情况下,观察到 50% 的存活率。
CKD-712 (2.5-20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可剂量依赖性地降低 LPS 诱导的 DIC 大鼠的肝、肾损伤标志物水平,在 20 mg/kg 剂量下,GOT (117.8 U/L) 和 BUN (11.8 mg/dL) 的降低幅度最大。
CKD-712 (20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可保护 DIC 大鼠免受 LPS 诱导的肝肺组织学损伤,减少炎症细胞浸润和组织坏死。
CKD-712 (1-20 mg/kg; 腹腔注射;单次给药) 可剂量依赖性地改善 LPS 诱导的脓毒症小鼠的存活率;在 LPS 处理前 30 分钟给药时,5 mg/kg 和 10 mg/kg 剂量组的存活率最高可达 92%。
CKD-712 (5-20 mg/kg; 腹腔注射;单次给药;酵母聚糖前 30 分钟) 可提高酵母聚糖诱导的脓毒症小鼠的存活率,在提前 30 分钟给药的 20 mg/kg 剂量下,观察到的存活率为 67%。
CKD-712 (2.5-20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可剂量依赖性地抑制 LPS 诱导的弥散性血管内凝血 (DIC) 大鼠的全身性炎症反应,在 10 mg/kg 剂量下对 TNF-α 的抑制作用最强 (降至 85.5 pg/mL)。
CKD-712 (20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可抑制 LPS 诱导的 DIC 大鼠肺细胞中 NF-κB 向细胞核的转位,从而减少促炎信号传导。
| Animal Model: |
ICR (male, 25-30 g, zymosan-induced endotoxemia sepsis model) |
| Dosage: |
5, 10, 20 mg/kg |
| Administration: |
Intraperitoneal (i.p.) single dose; 30 min pre-zymosan |
| Result: |
Achieved survival rates of 42%, 50%, and 67% at 5, 10, and 20 mg/kg respectively at 6 days post-zymosan (statistically significant at 20 mg/kg, p ≤ 0.05). |
| Animal Model: |
ICR (male, 25-30 g, LPS-induced hypothermia sepsis model) |
| Dosage: |
1, 3, 10, 20 mg/kg |
| Administration: |
Intraperitoneal (i.p.) single dose; 30 min pre-LPS |
| Result: |
Prevented LPS-induced hypothermia, maintaining significantly higher mean rectal temperatures compared to vehicle controls at 5 and 7 hours post-LPS (p ≤ 0.05).
Enabled all groups to recover to normal temperatures by 23 hours post-LPS. |
| Animal Model: |
ICR (male, 25-30 g, CLP-induced polymicrobial sepsis model) |
| Dosage: |
1, 3 mg/kg/day |
| Administration: |
Intraperitoneal (i.p.) once daily; 4 total doses (2 pre-surgery, 2 post-surgery) |
| Result: |
Improved final survival rates to 50% and 45% at 1 mg/kg/day and 3 mg/kg/day respectively, compared to 15% survival with CLP alone at 72 hours post-surgery.
Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model) |
| Animal Model: |
ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model) |
| Dosage: |
1, 3, 10, 20 mg/kg (4 hours post-LPS) |
| Administration: |
Intraperitoneal (i.p.) single dose |
| Result: |
Achieved survival rates of 33%, 40%, 40%, and 53% at 1, 3, 10, and 20 mg/kg respectively when administered 4 hours post-LPS. |
| Animal Model: |
ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model) |
| Dosage: |
2.5, 5, 10, 20 mg/kg (1 hour post-LPS) |
| Administration: |
Intraperitoneal (i.p.) single dose |
| Result: |
Achieved survival rates of 47%, 60%, 67%, and 67% at 1, 3, 10, and 20 mg/kg respectively when administered 1 hour post-LPS (statistically significant at 10, 20 mg/kg, p ≤ 0.05).
|
| Animal Model: |
Sprague-Dawley (SD) (male, 150-160 g, LPS-induced septic organ injury Dlc model) |
| Dosage: |
20 mg/kg |
| Administration: |
Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS) |
| Result: |
Inhibited LPS-induced translocation of NF-κB from the cytoplasm to the nucleus of lung pneumocytes, with NF-κB remaining localized to the cytoplasm.
Reduced liver sinusoidal enlargement and inflammatory cell infiltration caused by LPS.
Reduced lung pneumocyte hypertrophy, inflammatory cell infiltration, and central necrosis caused by LPS. |
| Animal Model: |
Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model) |
| Dosage: |
2.5, 5, 10, 20 mg/kg |
| Administration: |
Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS) |
| Result: |
LPS-induced GOT, GPT, BUN, creatinine, TNF-α, and IL-6 levels were all reduced in a dose-dependent manner at 2.5, 5, 10, and 20 mg/kg respectively. |
|